Pharmacist-perceived barriers to pharmaceutical care of chronic and end-stage kidney disease patients in Saudi Arabia

Suleiman, Amal K; Melaibari, Maryam; Alkhaldi, Turkiah; Almuhisen, Sara; Alharbi, Samar F; Kharshid, Abeer Mohammad; Alboghdadly, Amany; Shilbayeh, Sireen Abdul Rahim

doi:10.4103/2045-080x.181037

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 2.3% of the studies related to the managing of Cardio Vascular Diseases [ 54 – 56 ](CVDs), while 2.3% of the studies focused on the intervention on patients with Chronic Kidney Diseases (CKDs) [ 10 , 57 , 58 ] and 1.5% of the studies described the implementation of PCs in patients with respiratory diseases such as asthma [ 59 , 60 ]. All of them substantiated that pharmacists/ clinical pharmacists are an essential part of the health care team to provide early detection of chronic diseases, managing associated complications, and how the physicians strongly recommended the importance of integrating the pharmaceutical care services.…”

Section: Study Resultsmentioning

confidence: 99%

“…It’s also designed to make it easier for healthcare workers to keep track of DRP data during the pharmaceutical treatment process. Lack of knowledge about medications, lack of adherence to medications, suboptimal efficacy of medications prescribed, untreated conditions, selection of doses, inadequate training, lack of space for counseling, and the need for additional monitoring were all identified as DRPs that could affect the sustainability of PCs and the progression of chronic diseases in some of the included studies [ 10 , 58 , 62 ].…”

Section: Study Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of pharmaceutical care services in the Middle East Countries: a review of studies of 2013–2020

et al. 2023

View full text Add to dashboard Cite

Introduction Pharmaceutical care services (PCs) have evolved significantly over the last few decades, with a greater focus on patient’s safety and proven effectiveness in a wide range of contexts. Many of the evidence supporting this technique comes from the United States, the evaluation and adoption of (PCs) which differ greatly across the globe. Objective The goal of this study was to identify and assess the efficacy of pharmaceutical care services in various pharmaceutical aspects throughout seventeen Middle Eastern nations. Method The Arkesy and O’Malley technique was used to conduct a scoping review. It was conducted using PubMed/Medline, Scopus, Cochrane Library, Springer Link, Clinical Trials, and Web of Science etc. The Van Tulder Scale was utilized in randomized trials research, whereas the dawn and black checklists were used in non-randomized trials research. A descriptive and numerical analysis of selected research was done. The scope of eligible PCs, pharmaceutical implementers, study outcomes, and quality were all identified by a thematic review of research. Results There were about 431,753 citations found in this study, and 129 publications were found to be eligible for inclusion after analysing more than 271 full-text papers. The study design was varied, with 43 (33.3%) RCTs and 86 (66.7%) n-RCTs. Thirty-three (25.6%) of the studies were published in 2020. Jordan, Saudi Arabia, and Turkey were home to the majority of the studies (25.6%, 16.3%, and 11.6%) respectively. Thirty-seven studies (19.7%) were concerned with resolving drug related problems (DRPs), whereas 27 (14.4%) were concerned with increasing quality of life (QOL) and 23 (12.2%) with improving drug adherence. Additionally, the research revealed that the average ratings of the activities provided to patients improved every year. Conclusion Studies in the Middle East continue to provide evidence supporting the positive impact of pharmaceutical care services on both hard and soft outcomes measured in most studies. Yet there was rare focus on the value of the implemented services. Thus, rigorous evaluation of the economic impact of implemented pharmaceutical care services in the Middle East and assessment of their sustainability is must.

show abstract

Section: Study Resultsmentioning

confidence: 99%

Section: Study Resultsmentioning

confidence: 99%

Evaluation of pharmaceutical care services in the Middle East Countries: a review of studies of 2013–2020

et al. 2023

View full text Add to dashboard Cite

show abstract

Renal pharmacists’ perceptions and current practices of assessing medication adherence in dialysis patients

et al. 2017

View full text Add to dashboard Cite

Perception scores, scale reliability, and responses to current practices questionnaire. Results 41 pharmacists completed the survey (response rate, 91.1%). The majority (91.9%, n = 34; median = 8.0) agreed patients were nonadherent to medication. Time constraints (43.8%, n = 14) and hospital support (31.3%, n = 10) were perceived as barriers to assessment. Objective blood monitoring was frequently used to determine nonadherence (57.1%, n = 16), whereas subjective interviews were rarely conducted (27.6%, n = 8). Though all pharmacists support the presence of dedicated pharmacist for assessing adherence (100.0%, n = 33), only 24.2% were actually performing this function. Conclusion Pharmacists were rarely assigned for adherence assessment in dialysis settings. Established self-report methods were under-utilised compared to objective methods. Future research should investigate the effectiveness of pharmacists' involvement in facilitating adherence promotion and early identification of medication-related issues in dialysis patients.

show abstract

Pharmacist-perceived barriers to pharmaceutical care of chronic and end-stage kidney disease patients in Saudi Arabia

Cited by 2 publications

References 0 publications

Evaluation of pharmaceutical care services in the Middle East Countries: a review of studies of 2013–2020

Evaluation of pharmaceutical care services in the Middle East Countries: a review of studies of 2013–2020

Renal pharmacists’ perceptions and current practices of assessing medication adherence in dialysis patients

Contact Info

Product

Resources

About